Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2010 - 2026)

Jazz Pharmaceuticals has reported Cost of Revenue for 17 years, with the latest figure at $134.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 28.2% year-over-year to $134.1 million; the trailing twelve-month figure through Mar 2026 stood at $532.8 million (up 17.14% YoY), and the FY2025 full-year result was $503.3 million, up 12.92% from the prior year.
• Cost of Revenue for Q1 2026 stood at $134.1 million, down from $153.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $167.4 million in Q4 2022, with the low at $95.5 million in Q1 2024.
• Average Cost of Revenue over 5 years is $121.1 million, with a median of $116.3 million recorded in 2025.
• Year-over-year, Cost of Revenue soared 186.85% in 2022 and tumbled 35.92% in 2023.
• Tracing JAZZ's Cost of Revenue over 5 years: stood at $167.4 million in 2022, then tumbled by 35.92% to $107.2 million in 2023, then climbed by 20.02% to $128.7 million in 2024, then increased by 19.28% to $153.5 million in 2025, then dropped by 12.65% to $134.1 million in 2026.
• The last three Cost of Revenue figures came in at $134.1 million (Q1 2026), $153.5 million (Q4 2025), and $128.9 million (Q3 2025), per Business Quant data.

Peer Comparison